Mary Kay Fenton
2016 - Achillion Pharmaceuticals
In 2016, Mary Kay Fenton earned a total compensation of $1.1M as Executive Vice President and Chief Financial Officer at Achillion Pharmaceuticals, a 112% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $101,932 |
|---|---|
| Option Awards | $635,350 |
| Salary | $371,000 |
| Other | $8,310 |
| Total | $1,116,592 |
Fenton received $635.4K in option awards, accounting for 57% of the total pay in 2016.
Fenton also received $101.9K in non-equity incentive plan, $371K in salary and $8.3K in other compensation.
Rankings
In 2016, Mary Kay Fenton's compensation ranked 7,710th out of 14,075 executives tracked by ExecPay. In other words, Fenton earned more than 45.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,710 out of 14,075 | 45th |
Division Manufacturing | 2,921 out of 5,489 | 47th |
Major group Chemicals And Allied Products | 962 out of 1,895 | 49th |
Industry group Drugs | 746 out of 1,538 | 52nd |
Industry Pharmaceutical Preparations | 593 out of 1,176 | 50th |
Source: SEC filing on April 17, 2017.
Fenton's colleagues
We found four more compensation records of executives who worked with Mary Kay Fenton at Achillion Pharmaceuticals in 2016.
2016
Milind Deshpande
Achillion Pharmaceuticals
Chief Executive Officer
2016
Joel Barrish
Achillion Pharmaceuticals
Chief Scientific Officer
2016
David Apelian
Achillion Pharmaceuticals
Chief Medical Officer
2016
Joseph Truitt
Achillion Pharmaceuticals